Tiziana Life Sciences Ltd
TLSA.O- Latest Trade
- trading higher0.8USD
- Change
- 0
- % Change
0.00%
- Day Range
- 0.69 - 0.80
- 52-Week Range
- 0.53 - 4.68
As of Jul 6 2022. Values delayed up to 15 minutes
- Previous Close
- 0.80
- Open
- 0.69
- Volume
- 59,347.00
- 3 Month Average Trading Volume
- 1.94
- Shares Out (Mil)
- 194.61
- Market Cap
- 72.68
- Forward P/E --
- Dividend Yield
- -99,999.99
Key Statistics
2 mean rating - 2 analysts
- P/E Excl. Extra Items (TTM)
- -99,999.99
- Price To Sales (TTM)
- -99,999.99
- Price To Book (Quarterly)
- 3.24
- Price To Cash Flow (Per Share TTM)
- -99,999.99
- Total Debt/Total Equity (Quarterly)
- 2.35
- Long Term Debt/Equity (Quarterly)
- 0.86
- Return On Investment (TTM)
- -142.01
- Return On Equity (TTM)
- -110.65
2021 (millions USD)
About Tiziana Life Sciences Ltd
Company Information
Tiziana Life Sciences Ltd is a clinical stage biotechnology company. The Company is focused on the discovery and development of molecules and related diagnostics to treat unmet medical needs in oncology and immunology. Its lead product candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501), and Milciclib TZLS-201. Foralumab (TZLS-401) is a fully human engineered anti-human cluster of differentiation 3 (CD3) monoclonal antibody (mAb). Foralumab is developed for the treatment of neurodegenerative diseases such as progressive Multiple Sclerosis (MS), and Crohn’s disease. The Anti IL-6R mAb (TZLS-501) is a fully human engineered mAb targeting the interleukin-6 receptor (IL-6R). Anti-IL-6R antibody can be used in combination with Foralumab or other anti-inflammatory and anti-infective agents as therapy for COVID-19 and oncology indications. The Company has developed Milciclib TZLS-201 for the treatment of hepatocellular carcinoma (HCC).
Executive Leadership
- Gabriele M.A. Cerrone
- Executive Chairman of the Board
- Kunwar Shailubhai
- Chief Executive Officer, Chief Scientific Officer, Director
- Neil Graham
- Chief Medical Officer
- John P. Brancaccio
- Non-Executive Independent Director
- Willy Jules Simon
- Non-Executive Independent Director
Latest News
- MarketsHalliburton, Couchbase, Newmont, Wingstop, Chevron
The tech-heavy Nasdaq fell nearly 2% on Thursday as U.S. inflation rose to a four-decade high in February, cementing the chances of the Federal Reserve raising interest rate later this month.
- MarketsChevron Corp, Goldman Sachs, Inari Medical
Wall Street's main indexes fell on Thursday, with technology stocks leading the declines after data showed consumer prices surged in February, cementing the case for an interest rate hike by the Federal Reserve later this month.
- MarketsAsana, Build-A-Bear, Pilgrim's Pride
Wall Street's main indexes were set to open lower on Thursday after data showed consumer prices in February surged as expected, cementing the case for an interest rate hike by the Federal Reserve later this month.
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,762.60 | 0.05%Positive |
| Copper | 642.40 | 1.36%Negative |
| Brent Crude Oil | 103.91 | 1.11%Positive |
| CBOT Soybeans | 1,582.75 | 0.48%Positive |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 3,831.39 | -- |
| Euro STOXX 50 | 3,413.27 | 1.59%Positive |
| FTSE 100 | 7,149.97 | 1.77%Positive |
| Nikkei 225 | 26,107.65 | 1.20%Negative |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes